The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

ClinicalTrials & Tribulations

Does salpingectomy prevent ovarian cancer? Let’s prove it.

The SOROCk clinical trial, NRG CC008 (NCT04251052)

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Abstract

The majority of epithelial ovarian cancer is diagnosed at an advanced stage and long-term survival is low. Since ovarian cancer screening is ineffective, the main focus to reduce ovarian cancer mortality is prevention. 

For individuals at increased risk of ovarian carcinoma, risk-reducing bilateral salpingo-oophorectomy (RRSO) is highly effective, but uptake at the recommended age is suboptimal, likely due to concerns about premature menopause. 

Mounting evidence suggests that many “ovarian” cancers originate in the fallopian tube, making bilateral salpingectomy with delayed oophorectomy an attractive, but as of yet, unproven option for risk-reduction in those who decline RRSO. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Kathryn P. Pennington, MD
Assistant professor, Division of Gynecologic Oncology, University of Washington School of Medicine
Warner K. Huh, MD
Professor & chair, Department of Obstetrics and Gynecology; Division of Gynecologic Oncology, University of Alabama School of Medicine
Sandra Russo, MD, PhD, MPH
Medical officer, Division of Cancer Prevention, National Cancer Institute
Joan L. Walker, MD
Professor, Division of Gynecologic Oncology, Stephenson Cancer Center, Oklahoma University Health Sciences Center
Table of Contents

YOU MAY BE INTERESTED IN

California state-funded institute scraps selection process that put cancer projects at a disadvantage
Cancer researchers are resubmitting applications to the California Institute for Regenerative Medicine

The California Institute for Regenerative Medicine, a state agency tasked with awarding billions of dollars of scientific funding for stem cell and gene therapy, has rescinded a controversial policy that was disrupting the flow of funding to cancer research.
By Sara Willa Ernst
PodcastThe Directors

The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes

Leadership is changing at The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute in the months to come—but the leaders of the two institutions say that this will have little if any effect on the clinical-research collaboration that they have spent the past 15years building (The Cancer Letter, July 12, 2019). 
By Sara Willa Ernst and Paul Goldberg
Drugs & Targets

FDA approves relacorilant + nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

FDA approved relacorilant (Lifyorli), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
Byline
Kathryn P. Pennington, MD
Assistant professor, Division of Gynecologic Oncology, University of Washington School of Medicine
Warner K. Huh, MD
Professor & chair, Department of Obstetrics and Gynecology; Division of Gynecologic Oncology, University of Alabama School of Medicine
Sandra Russo, MD, PhD, MPH
Medical officer, Division of Cancer Prevention, National Cancer Institute
Joan L. Walker, MD
Professor, Division of Gynecologic Oncology, Stephenson Cancer Center, Oklahoma University Health Sciences Center
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account